Founded in 2007, we are a Sydney-based regenerative medicine company developing a portfolio of novel cell-based therapies targeting unmet medical needs in human, with an initial focus on osteoarthritis (OA), neuropathic pain and dermatology. All of the products in our pipeline are underpinned by proprietary stem cell technologies. Regeneus listed on the Australian Stock Exchange (ASX: RGS) in September 2013.
Regenerative medicine is a rapidly advancing interdisciplinary field in healthcare that focuses on repairing and regenerating cells, tissues and organs with the goal to enhance the body’s natural ability to replace or repair tissue damaged or destroyed by injury or disease.
Our stem cell technologies use mesenchymal stem cells (MSCs) from adipose tissue. MSCs are responsible for promoting the body’s natural healing, by reducing inflammation, promoting tissue repair and reducing scarring. MSCs from adipose tissue are found in much greater numbers than other tissue types (e.g. bone marrow, blood) and are readily available throughout the whole body. Our stem cell technology platform allows for scalable production of allogeneic cell products for a wide range of therapeutic indications, optimising the licensing prospects for each technology platform. We have developed technology and protocols for the production of cell secretions from MSCs for the treatment of inflammatory skin conditions (Sygenus).
Our substantial intellectual property (IP) covers a broad range of clinical indications across our product portfolio, creating value for partnering with larger companies for global commercialisation.
We are led by an experienced Board and management team whom we leverage the scientific, corporate and commercial experience from to develop novel cell therapies, including vast experience in manufacturing and logistical capabilities, protection and translation into clinic driven through strategic partners.